← Human Trials & Peer-Reviewed Studies
The human insulin analog insulin lispro improves insulin binding on circulating monocytes of intensively treated insulin-dependent diabetes mellitus patients
Plain-language guide to PMID 8964871 (1996): crossover randomized controlled trial study of Insulin Lispro.
Key Facts
- PMID
- 8964871
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 1996
- Study type
- Randomized Controlled Trial
- Authors
- Jehle PM et al. (6 authors)
- DOI
- 10.1210/jcem.81.6.8964871
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Insulin Lispro, published as a randomized controlled trial.
The aim of this study was to investigate whether intensified treatment with either LP or RI influences insulin receptor status.
Why It Was Studied
The rapidly absorbed analog of human insulin, insulin lispro (LP), is characterized by a faster onset of action, a higher peak insulin level, and a shorter duration of action compared with regular insulin (RI).
Four patients began with LP, whereas eight patients started with RI.
Who Took Part
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
Twelve patients with insulin-dependent diabetes mellitus (IDDM) participating in a multicenter randomized cross-over trial were allocated to this study.
How the Study Was Run
In design terms this was a randomized, crossover and multicenter study.
Because people in this Insulin Lispro study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Each person switched between Insulin Lispro and the comparison at some point, usually with a gap in between.
More than one site took part, so the participants came from several places.
What Was Measured
The rapidly absorbed analog of human insulin, insulin lispro (LP), is characterized by a faster onset of action, a higher peak insulin level, and a shorter duration of action compared with regular insulin (RI).
PubMed files the paper under topics including Cell Line, Diabetes Mellitus, Type 1, Down-Regulation, Eating, Insulin, Insulin Lispro and Lymphocytes.
What This Means in Plain Language
The paper is a randomized, crossover and multicenter study of Insulin Lispro.
The publication is from 1996 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Insulin Lispro compound page, all human trials.
Our Notes on the Compound
Insulin Lispro: A rapid-acting mealtime insulin analog; brands include Humalog, Admelog and Lyumjev.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.